Multimeric scaffolds displaying the HIV-1 Envelope mper induce mper-specific antibodies and cross-neutralizing antibodies when Co-Immunized with gp160 DNA

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Krebs, Shelly J ^a   McBurney, Sean P ^a   Kovarik, Dina N ^c   Waddell, Chelsea D ^a   Jaworski, J Pablo ^a   Sutton, William F ^a   Gomes, Michelle M ^a   Trovato, Maria ^b   Waagmeester, Garret ^a   Barnett, Susan J ^d   DeBerardinis, Piergiuseppe ^b   Haigwood, Nancy L ^a,c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b INSTITUTE OF PROTEIN BIOCHEMISTRY   (Italy)

^c SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^d Novartis Vaccines and Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; NEUTRALIZING ANTIBODY; VIRUS DNA; VIRUS VACCINE; BACTERIAL PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PRIMER DNA; VIRUS ANTIBODY;

AMINO TERMINAL SEQUENCE; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; GEOBACILLUS STEAROTHERMOPHILUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IMMUNE RESPONSE; IMMUNIZATION; MEMBRANE PROXIMAL EXTERNAL REGION; NEW ZEALAND RABBIT; NONHUMAN; PROMOTER REGION; PROTEIN DOMAIN; PROTEIN TARGETING; VIRUS ATTACHMENT; VIRUS ENVELOPE; VIRUS NEUTRALIZATION; VIRUS PARTICLE; ANALYSIS OF VARIANCE; ANIMAL; BIOLISTIC TRANSFORMATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; IMMUNOLOGY; METABOLISM; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; RABBIT; SERODIAGNOSIS; WESTERN BLOTTING;

AIDS VACCINES; ANALYSIS OF VARIANCE; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BACTERIAL PROTEINS; BIOLISTICS; BLOTTING, WESTERN; DNA PRIMERS; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GEOBACILLUS STEAROTHERMOPHILUS; HIV ENVELOPE PROTEIN GP160; HIV ENVELOPE PROTEIN GP41; HIV-1; NEUTRALIZATION TESTS; PLASMIDS; RABBITS;

EID: 84929498995     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113463     Document Type: Article

References (71)

1. WHO (2012) UNAIDS REPORT ON THE GLOBAL AIDS EPIDEMIC 2010.
2. McBurney SP, Ross TM (2008) Viral sequence diversity: challenges for AIDS vaccine designs. Expert Review of Vaccines 7: 1405-1417.
3. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, et al. (2008) The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 6: 143- 155.
4. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, et al. (2002) Diversity considerations in HIV-1 vaccine selection. Science 296: 2354-2360.
5. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
6. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, et al. (2009) Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers. PLoS Pathog 5: E1000433.
7. Mascola JR (2002) Passive transfer studies to elucidate the role of antibody-mediated protection against HIV-1. Vaccine 20: 1922-1925.
8. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, et al. (1999) Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies. J Virol 73: 4009-4018.
9. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6: 207-210.
10. Parren PWHI, Marx PA, Hessell AJ, Luckay A, Harouse J, et al. (2001) Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro. Journal of Virology 75: 8340-8347.
11. Frey G, Chen J, Rits-Volloch S, Freeman MM, Zolla-Pazner S, et al. (2010) Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies. Nat Struct Mol Biol 17: 1486-1491.
12. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, et al. (2001) A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 17: 1757-1765.
13. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, et al. (1993) A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 67: 6642-6647.
14. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, et al. (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 75: 10892-10905.
15. Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, et al. (2008) A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci U S A 105: 3739-3744.
16. Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, et al. (2012) Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491: 406-412.
17. Pejchal R, Gach JS, Brunel FM, Cardoso RM, Stanfield RL, et al. (2009) A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J Virol 83: 8451-8462.
18. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004) Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 78: 13232-13252.
19. Mehandru S, Wrin T, Galovich J, Stiegler G, Vcelar B, et al. (2004) Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J Virol 78: 14039-14042.
20. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, et al. (2010) Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84: 1302-1313.
21. Zwick MB (2005) The membrane-proximal external region of HIV-1 gp41: A vaccine target worth exploring. AIDS 19: 1725-1737.
22. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
23. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366: 1275-1286.
24. Wahome N, Pfeiffer T, Ambiel I, Yang Y, Keppler OT, et al. (2012) Conformation-specific display of 4E10 and 2F5 epitopes on self-assembling protein nanoparticles as a potential HIV vaccine. Chem Biol Drug Des 80: 349-357.
25. Kim M, Qiao Z, Yu J, Montefiori D, Reinherz EL (2007) Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state. Vaccine 25: 5102-5114.
26. Law M, Cardoso RM, Wilson IA, Burton DR (2007) Antigenic and immunogenic study of membraneproximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy. J Virol 81: 4272-4285.
27. Phogat S, Svehla K, Tang M, Spadaccini A, Muller J, et al. (2008) Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology 373: 72-84.
28. Correia BE, Ban YE, Holmes MA, Xu H, Ellingson K, et al. (2010) Computational design of epitopescaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. Structure 18: 1116-1126.
29. Kamdem Toukam D, Tenbusch M, Stang A, Temchura V, Storcksdieck genannt Bonsmann M, et al. (2012) Targeting Antibody Responses to the Membrane Proximal External Region of the Envelope Glycoprotein of Human Immunodeficiency Virus. PLoS One 7: E38068.
30. Zhou M, Meyer T, Koch S, Koch J, von Briesen H, et al. (2013) Identification of a new epitope for HIVneutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library. European journal of immunology 43: 499-509.
31. Luo M, Yuan F, Liu Y, Jiang S, Song X, et al. (2006) Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment. Vaccine 24: 435-442.
32. Ye L, Wen Z, Dong K, Wang X, Bu Z, et al. (2011) Induction of HIV Neutralizing Antibodies against the MPER of the HIV Envelope Protein by HA/gp41 Chimeric Protein-Based DNA and VLP Vaccines. PLoS One 6: E14813.
33. Wang J, Tong P, Lu L, Zhou L, Xu L, et al. (2011) HIV-1 gp41 Core with Exposed Membrane-Proximal External Region Inducing Broad HIV-1 Neutralizing Antibodies. PLoS One 6: E18233.
34. Arnold GF, Velasco PK, Holmes AK, Wrin T, Geisler SC, et al. (2009) Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol 83: 5087-5100.
35. Yi G, Lapelosa M, Bradley R, Mariano TM, Dietz DE, et al. (2013) Chimeric Rhinoviruses Displaying MPER Epitopes Elicit Anti-HIV Neutralizing Responses. PLoS One 8: E72205.
36. Yi G, Lapelosa M, Bradley R, Mariano TM, Dietz DE, et al. (2013) Correction: Chimeric Rhinoviruses Displaying MPER Epitopes Elicit Anti-HIV Neutralizing Responses. PLoS One 8, e72205.
37. Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, et al. (2011) Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34: 269-280.
38. Caivano A, Doria-Rose NA, Buelow B, Sartorius R, Trovato M, et al. (2010) HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNgamma production by CD4+ T cells. Virology 407: 296-305.
39. Jaworski JP, Krebs SJ, Trovato M, Kovarik DN, Brower Z, et al. (2012) Co-Immunization with Multimeric Scaffolds and DNA Rapidly Induces Potent Autologous HIV-1 Neutralizing Antibodies and CD8 T Cells. PLoS One 7: E31464.
40. Domingo GJ, Orru S, Perham RN (2001) Multiple display of peptides and proteins on a macromolecular scaffold derived from a multienzyme complex. J Mol Biol 305: 259-267.
41. Perham RN (1995) Structure and posttranslational modification of lipoyl domain of 2-oxo-acid dehydrogenase multienzyme complexes. Methods Enzymol 251: 436-448.
42. Domingo GJ, Chauhan HJ, Lessard IA, Fuller C, Perham RN (1999) Self-assembly and catalytic activity of the pyruvate dehydrogenase multienzyme complex from Bacillus stearothermophilus. Eur J Biochem 266: 1136-1146.
43. Lessard IA, Perham RN (1995) Interaction of component enzymes with the peripheral subunit-binding domain of the pyruvate dehydrogenase multienzyme complex of Bacillus stearothermophilus: Stoichiometry and specificity in self-assembly. Biochem J 306 (Pt 3): 727-733.
44. Saunders CJ, McCaffrey RA, Zharkikh I, Kraft Z, Malenbaum SE, et al. (2005) The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. J Virol 79: 9069-9080.
45. Lu S, Wyatt R, Richmond JF, Mustafa F, Wang S, et al. (1998) Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS research and human retroviruses 14: 151-155.
46. Saunders CJ, McCaffrey RA, Zharkikh I, Kraft Z, Malenbaum SE, et al. (2005) The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner. Journal of virology 79: 9069-9080.
47. Planelles V, Haigwood NL, Marthas ML, Mann KA, Scandella C, et al. (1991) Functional and immunological characterization of SIV envelope glycoprotein produced in genetically engineered mammalian cells. AIDS Res Hum Retroviruses 7: 889-898.
48. Malherbe DC, Doria-Rose NA, Misher L, Beckett T, Puryear WB, et al. (2011) Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J Virol 85: 5262-5274.
49. Shibata R, Igarashi T, Haigwood N, Buckler-White A, Ogert R, et al. (1999) Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nature Medicine 5: 204-210.
50. Blay WM, Kasprzyk T, Misher L, Richardson BA, Haigwood NL (2007) Mutations in envelope gp120 can impact proteolytic processing of the gp160 precursor and thereby affect neutralization sensitivity of human immunodeficiency virus type 1 pseudoviruses. J Virol 81: 13037-13049.
51. Long EM, Rainwater SM, Lavreys L, Mandaliya K, Overbaugh J (2002) HIV type 1 variants transmitted to women in Kenya require the CCR5 coreceptor for entry, regardless of the genetic complexity of the infecting virus. AIDS Res Hum Retroviruses 18: 567-576.
52. Reed La HM (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27: 493-497.
53. Tomaras GD, Binley JM, Gray ES, Crooks ET, Osawa K, et al. (2011) Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J Virol 85: 11502-11519.
54. Wei X, Decker JM, Liu H, Zhang Z, Arani RB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896-1905.
55. Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, et al. (2006) Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol 80: 8745-8762.
56. Sanders RW, Schiffner L, Master A, Kajumo F, Guo Y, et al. (2000) Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits. J Virol 74: 5091-5100.
57. Wyatt R, Sullivan N, Thali M, Repke H, Ho D, et al. (1993) Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. Journal of virology 67: 4557-4565.
58. Lu S (1998) Developing DNA vaccines against immunodeficiency viruses. Curr Top Microbiol Immunol 226: 161-173.
59. Binley JM, Sanders RW, Clas B, Schuelke N, Master A, et al. (2000) A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 74: 627-643.
60. Jaworski JP, Krebs SJ, Trovato M, Kovarik DN, Brower Z, et al. (2012) Co-immunization with multimeric scaffolds and DNA rapidly induces potent autologous HIV-1 neutralizing antibodies and CD8+ T cells. PLoS One 7: E31464.
61. Patel V, Jalah R, Kulkarni V, Valentin A, Rosati M, et al. (2013) DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge. Proc Natl Acad Sci U S A 110: 2975-2980.
62. Li J, Valentin A, Kulkarni V, Rosati M, Beach RK, et al. (2013) HIV/SIV DNA vaccine combined with protein in a co-immunization protocol elicits highest humoral responses to envelope in mice and macaques. Vaccine 31: 3747-55.
63. Zolla-Pazner S, Cardozo T (2010) Structure-function relationships of HIV-1 envelope sequencevariable regions refocus vaccine design. Nature reviews Immunology 10: 527-535.
64. Montero M, Gulzar N, Klaric KA, Donald JE, Lepik C, et al. (2012) Neutralizing epitopes in the membrane-proximal external region of HIV-1 gp41 are influenced by the transmembrane domain and the plasma membrane. J Virol 86: 2930-2941.
65. Cardozo T, Kimura T, Philpott S, Weiser B, Burger H, et al. (2007) Structural basis for coreceptor selectivity by the HIV type 1 V3 loop. AIDS research and human retroviruses 23: 415-426.
66. Almond D, Kimura T, Kong X, Swetnam J, Zolla-Pazner S, et al. (2010) Structural conservation predominates over sequence variability in the crown of HIV type 1's V3 loop. AIDS Res Hum Retroviruses 26: 717-723.
67. Rolland M, Edlefsen PT, Larsen BB, Tovanabutra S, Sanders-Buell E, et al. (2012) Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490: 417-420.
68. Derby NR, Kraft Z, Kan E, Crooks ET, Barnett SW, et al. (2006) Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol 80: 8745-8762.
69. Jaworski JP, Kobie J, Brower Z, Malherbe DC, Landucci G, et al. (2013) Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in SHIVSF162P3-infected infant rhesus macaques. J Virol 87: 10447-59.
70. Menendez A, Chow KC, Pan OC, Scott JK (2004) Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope. J Mol Biol 338: 311-327.
71. Wang J, Xu L, Tong P, Chen YH (2011) Mucosal antibodies induced by tandem repeat of 2F5 epitope block transcytosis of HIV-1. Vaccine 29: 8542-8548.